Sture Lindegren
-
- Radiopharmaceutical Chemistry and Applications 72
- Monoclonal and Polyclonal Antibodies Research 33
- Medical Imaging Techniques and Applications 27
- Radiation top 5%
-
- Medical Imaging and Pathology Studies 17
- Radiation Therapy and Dosimetry 6
- Lung Cancer Treatments and Mutations 5
- Oncology top 10%
- Peptidase Inhibition and Analysis 11
-
- Neuroendocrine Tumor Research Advances 7
- Co-authors
- Tom BäckHolger JensenLars JacobssonStig PalmRagnar HultbornHåkan AnderssonJörgen ElgqvistPer Albertsson
- Journals
- SHILAP Revista de lepidopterología (1 paper)PLoS ONE (2 papers)Cancer (1 paper)
In The Last Decade
Sture Lindegren
78 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 78
- Radiology, Nuclear Medicine and Imaging 1.7k
- Radiation 230
- Pulmonary and Respiratory Medicine 708
- Oncology 413
- Pathology and Forensic Medicine 99
Countries citing papers authored by Sture Lindegren
This map shows the geographic impact of Sture Lindegren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sture Lindegren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sture Lindegren more than expected).
Fields of papers citing papers by Sture Lindegren
This network shows the impact of papers produced by Sture Lindegren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sture Lindegren. The network helps show where Sture Lindegren may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sture Lindegren, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 5 | |
| 5 | 2024 | 12 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 12 | |
| 8 | 2023 | 49 | |
| 9 | 2021 | 11 | |
| 10 | 2020 | 69 | |
| 11 | Preclinical evaluation of astatinated nanobodies for targeted alpha therapy | 2017 | 1 |
| 12 | 2015 | 6 | |
| 13 | 2014 | 7 | |
| 14 | 2014 | 9 | |
| 15 | 2012 | 18 | |
| 16 | 2011 | 9 | |
| 17 | 2011 | 34 | |
| 18 | 2008 | 66 | |
| 19 | Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. | 2005 | 43 |
| 20 | Astatine-211-labeled Antibodies for Treatment of Disseminated Ovarian Cancer | 2003 | 3 |
About Sture Lindegren
Sture Lindegren is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology, having authored 79 papers that have together received 1.9k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (72 papers), Monoclonal and Polyclonal Antibodies Research (33 papers), Medical Imaging Techniques and Applications (27 papers), Medical Imaging and Pathology Studies (17 papers), Peptidase Inhibition and Analysis (11 papers), Neuroendocrine Tumor Research Advances (7 papers), Radiation Therapy and Dosimetry (6 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (1.7k citations), Radiation (230 citations) and Pulmonary and Respiratory Medicine (708 citations). Sture Lindegren has collaborated with scholars based in Sweden, Denmark and France. Frequent co-authors include Tom Bäck, Holger Jensen, Lars Jacobsson, Stig Palm, Ragnar Hultborn, Håkan Andersson, Jörgen Elgqvist, Per Albertsson, Emma Aneheim and Sofia H.L. Frost. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.